What is Heron Therapeutics, Inc. (HRTX) stock price today?

Heron Therapeutics, Inc. (HRTX) is currently trading at $0.41, up 13.37% today.

What is HRTX P/E ratio?

Heron Therapeutics, Inc.'s P/E ratio is -1.86. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is HRTX return on equity (ROE)?

Heron Therapeutics, Inc.'s return on equity (ROE) is -300.90%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Heron Therapeutics, Inc.'s market cap?

Heron Therapeutics, Inc. has a market capitalization of $76.87M.

NASDAQ · Biotechnology

Heron Therapeutics, Inc. (HRTX) Stock

$0.41 +13.37% NASDAQ: HRTX Healthcare

Valuation

Metric	Value
Price	$0.41
Market Cap	$76.87M
P/E Ratio	-1.86
P/B Ratio	9.58
P/S Ratio	0.44
EPS (TTM)	$-0.12
52-Week High	$1.58
52-Week Low	$0.26
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-300.90%
ROA	-13.50%
ROCE	-6.79%
Gross Margin	-1.29%
Operating Margin	-1.94%
Net Margin	-22.52%
Debt/Equity	21.48
Current Ratio	2.48

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$86.0M	$108.0M	$127.0M	$144.0M	$155.0M
Operating Profit	$-218.0M	$-175.0M	$-111.0M	$-12.0M	$-3.0M
Net Profit	$-221.0M	$-182.0M	$-111.0M	$-14.0M	$-20.0M
EPS	$-2.24	$-1.67	$-0.80	$-0.09	$-0.12
Op Margin	-252.3%	-162.2%	-87.1%	-8.0%	-1.6%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$306.0M	$251.0M	$223.0M	$233.0M	$256.0M
Total Liabilities	$228.0M	$237.0M	$256.0M	$267.0M	$242.0M
Cash	$91.0M	$15.0M	$29.0M	$26.0M	$29.0M
Borrowings	$159.0M	$157.0M	$180.0M	$178.0M	$141.0M

Latest News

New Strong Sell Stocks for July 15th Zacks · Jul 15, 2026 Heron Therapeutics (HRTX) Stock Sees Fair Value Cut After Cinvanti Patent Decision Simply Wall St. · Jul 12, 2026 Is Heron Therapeutics, Inc. (HRTX) Stock a Recovery Opportunity After Cinvanti Patent Court Ruling? Insider Monkey · Jun 30, 2026 Heron Therapeutics Receives Nasdaq Minimum Bid Price Notification MT Newswires · Jun 26, 2026 Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today? Stocktwits · Jun 3, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-203.0M	$-147.0M	$-59.0M	$-23.0M	$-28.0M
Investing Cash Flow	$30.0M	$-5.0M	$16.0M	$17.0M	$16.0M
Financing Cash Flow	$0	$0	$0	$0	$-150.0M
Net Cash Flow	$-15.0M	$-75.0M	$13.0M	$-3.0M	$3.0M
Free Cash Flow	$-206.0M	$-149.0M	$-60.0M	$-24.0M	$-28.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.01
EV / EBITDA	-6.95
FCF Yield	-18.44%
Quick Ratio	1.51
Interest Coverage	-2.79
Return 1Y	-79.18%
Return 3Y	-66.56%
Return 5Y	-96.70%

Ownership

Insiders Held0.90%

Institutions Held82.23%

Institutions Float Held82.98%

Institutional Holder	Shares	Report Date
Rubric Capital Management LP	30,046,828	2026-03-31
Clearline Capital, LP	12,235,239	2026-03-31
Blackrock Inc.	10,106,422	2026-03-31
Orbimed Advisors LLC.	9,816,940	2026-03-31
Velan Capital Investment Management LP	8,753,290	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
CHRSCoherus Oncology, Inc.	$1.07	+0.00%	-1.10	$165.32M	0.00%
EPRXEupraxia Pharmaceuticals Inc.	$7.46	-1.45%	-7.10	$249.76M	0.00%
GNFTGenfit S.A.	$8.95	+4.07%	261.07	$445.68M	0.00%
IVVDInvivyd, Inc.	$0.72	+2.97%	-2.08	$212.47M	0.00%
MDWDMediWound Ltd.	$12.54	+0.97%	-8.45	$161.09M	0.00%

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. is led by CEO Craig Alexander Collard, employs 122 people, headquartered in US, publicly traded since 1987.

Heron Therapeutics, Inc. (HRTX) stock trades at $0.41 with a market capitalization of $76.87M. The stock is valued at a price-to-earnings (P/E) ratio of -1.86, price-to-book of 9.58, price-to-sales of 0.44. Over the past 52 weeks the stock has ranged between $0.26 and $1.58, and currently trades 74.1% below its 52-week high.

On profitability, Heron Therapeutics, Inc. generates a return on equity (ROE) of -300.90%, return on capital employed of -6.79%, an operating margin of -1.94%, a net profit margin of -22.52%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides